

SUPPORTING INFORMATION FOR

Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents

Ngo Xuan Hoang,^a Van-Hai Hoang,^b Thi-Thu-Trang Luu,^c Hung N. Luu,^{d,e} Thien Ngo,^f Duong Van Hieu,^a Nguyen Huu Long,^a Le Viet Anh,^a Son Tung Ngo,^{g,h} Yen Thi Kim Nguyen,ⁱ Byung Woo Han,ⁱ Thanh Xuan Nguyen,^j Dinh Thi Thanh Hai,^a Tran Thi Thu Hien,^k and Phuong-Thao Tran^{*a}

- ^a. Hanoi University of Pharmacy, 13-15 Le Thanh Tong, Hanoi 100000, Viet Nam.
- ^b. Laboratory of Medicinal Chemistry, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
- ^c. College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Seoul 08826, Republic of Korea.
- ^d. Division of Cancer Control and Population Sciences, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA.
- ^e. Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA.
- ^f. Faculty of Pharmacy, Thai Binh University of Medicine and Pharmacy, Thai Binh city 410000, Vietnam.
- ^g. Laboratory of Theoretical and Computational Biophysics, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
- ^h. Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 700000, Vietnam.
- ⁱ. College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea
- ^j. Department of Surgical Oncology, Viet-Duc University Hospital, Hanoi 100000, Vietnam.
- ^k. Vietnam University of Traditional Medicine, 2 Tran Phu, Ha Dong, Hanoi 100000, Vietnam

Email: thaotp119@gmail.com

Chemistry

1-Methyl-6-nitro-2H-indazole (12). Prepared from commercially available 6-nitroindazole (**9**) following the general procedure 1 to afford a yellow solid, yield 54.8%. mp 124-126 °C. ¹H NMR (500 MHz, CDCl₃, ppm): δ 8.31 (s, *J* = 1.00 Hz, 1H), 8.03 (d, *J* = 0.50 Hz, 1H), 7.96 (dd, *J* = 9.00, 2.00 Hz, 1H), 7.77 (d, *J* = 8.50 Hz, 1H), 4.12 (3H).

1,3-Dimethyl-6-nitro-1H-indazole (13). Prepared from commercially available 3-methyl-6-nitroindazole (**10**) and iodomethane following the general procedure 1 to afford a yellow solid, yield 52.3%. mp 175-177 °C. ¹H NMR (300MHz, CDCl₃) δ 8.58 (dd, *J* = 1.83, 0.75 Hz, 1H), 7.81 (dd, *J* = 9.15, 2.01 Hz, 1H), 7.63 (dd, *J* = 9.15, 0.57 Hz, 1H), 4.16 (s, 3H), 2.56 (s, 3H).

2-Dimethyl-6-nitro-2H-indazole (14). Prepared from commercially available 6-nitroindazole (**9**) following the general procedure 1 to afford a yellow solid, yield 43.9%. mp 164-166 °C. ¹H NMR (500 MHz, CDCl₃, ppm): δ 8.59 (s, 1H), 7.95 (s, 1H), 7.82 (dd, *J* = 9.00, 1.50 Hz, 1H), 7.68 (d, *J* = 9.50 Hz, 1H), 4.23 (s, 3H).

2,3-Dimethyl-6-nitro-1H-indazole (15). Prepared from commercially available 3-methyl-6-nitroindazole (**10**) and iodomethane following the general procedure 1 to afford a yellow solid, yield 42.8%. mp 183-185 °C. ¹H NMR (500 MHz, CDCl₃, ppm): δ 8.59 (dd, *J* = 1.83, 0.75 Hz, 1H), 7.83

(dd, $J = 9.15, 2.01$ Hz, 1H), 7.64 (dd, $J = 9.15, 0.57$ Hz, 1H), 4.15 (s, 3H), 2.64 (s, 3H).

1-Methyl-1H-indazol-6-amine (16). Prepared from compound **12** following the general procedure 2 to afford a reddish solid, yield 91.0%. mp 87-89 °C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.79 (s, 1H), 7.47 (d, $J = 8.50$ Hz, 1H), 6.56 (dd, $J = 8.50, 1.50$ Hz, 1H), 6.51 (d, $J = 0.50$ Hz, 1H), 3.92 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 145.7, 141.5, 132.7, 121.8, 117.9, 112.4, 91.61, 35.1. ESI-MS m/z 147.8 $[\text{M}+\text{H}]^+$.

1,3-Dimethyl-1H-indazol-6-amine (17). Prepared from compound **13** following the general procedure 2 to afford a reddish solid, yield 85.6%. mp 92-94 °C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.33 (d, $J = 8.50$ Hz, 1H), 7.19 (s, 1H), 6.49 (dd, $J = 8.50, 1.50$ Hz, 1H), 6.42 (s, 1H), 3.78 (s, 3H), 2.41 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 145.2, 142.4, 141.3, 121.3, 117.5, 111.6, 92.1, 34.8, 11.7. ESI-MS m/z 161.8 $[\text{M}+\text{H}]^+$.

2-Methyl-2H-indazol-6-amine (18). Prepared from compound **14** following the general procedure 2 to afford a reddish solid, yield 95.7%. mp 81-83 °C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.64 (s, 1H), 7.37 (d, $J = 9.00$ Hz, 1H), 6.72 (t, $J = 1.00$ Hz, 1H), 6.51 (dd, $J = 9.00, 1.50$ Hz, 1H), 4.03 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 150.5, 144.6, 123.6, 120.7, 117.1, 116.0, 96.9, 39.9. ESI-MS m/z 147.8 $[\text{M}+\text{H}]^+$.

2,3-Dimethyl-2H-indazol-6-amine (19). Prepared from compound **15** following the general procedure 2 to afford a reddish solid, yield 93.2%. mp 78-80 °C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.35 (d, $J = 8.50$ Hz, 1H), 6.72 (s, 1H), 6.54 (dd, $J = 8.50, 1.50$ Hz, 1H), 3.99 (s, 3H), 2.51 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 149.0, 144.7, 131.5, 120.4, 116.3, 114.7, 96.6, 36.8, 9.86. ESI-MS m/z 161.8 $[\text{M}+\text{H}]^+$.

N-(1-Methyl-1H-indazol-6-yl)acetamide (20). Prepared from compound **16** following the general procedure 4 to afford a white solid, yield 91.4%. mp 126-128 °C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 8.13 (s, 1H), 7.88 (s, 1H), 7.59 (d, $J = 8.50$ Hz, 1H), 7.40 (br, 1H), 6.78 (d, $J = 8.45$ Hz, 1H), 4.02 (s, 3H), 2.21 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 168.6, 140.4, 136.4, 132.5, 121.4, 120.7, 114.2, 99.3, 35.5, 24.7. ESI-MS m/z 190.06 $[\text{M}+\text{H}]^+$.

N-(1,3-Dimethyl-1H-indazol-6-yl)acetamide (21). Prepared from compound **17** following the general procedure 4 to afford a white solid, yield 89.3%. mp 122-124 °C. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 8.03 (s, 1H), 7.50 (d, $J = 8.43$ Hz, 1H), 7.47 (br, 1H), 6.76 (dd, $J = 8.43, 1.47$ Hz, 1H), 3.93 (s, 3H), 2.50 (s, 3H), 2.20 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 168.5, 141.3, 141.1, 136.4, 120.7, 120.1, 113.2, 99.2, 35.1, 24.7, 11.7. ESI-MS m/z 204.08 $[\text{M}+\text{H}]^+$.

N-(2-Methyl-2H-indazol-6-yl)acetamide (22). Prepared from compound **18** following the general procedure 4 to afford a white solid, yield 90.3%. mp 118-120 °C. IR (KBr, cm^{-1}): 3242 (NH

amide); 3099 (CH aromatic); 1658 (C=O amide); 1643 (C=N); 1575, 1506 (C=C aromatic). ^1H NMR (500 MHz, CD_3OD , ppm): δ 8.10 (s, 1H), 8.03 (s, 1H), 7.60 (d, J = 8.95 Hz, 1H), 7.08 (dd, J = 8.95, 1.65 Hz, 1H), 4.15 (s, 3H), 2.14 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 168.4, 149.1, 135.8, 123.6, 120.5, 119.5, 117.3, 106.2, 45.8, 24.6. ESI-MS m/z 190.04 $[\text{M}+\text{H}]^+$.

***N*-(2,3-Dimethyl-2H-indazol-6-yl)acetamide (23).** Prepared from compound **19** following the general procedure 4 to afford a white solid, yield 92.4%. mp 115-117°C. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.76 (s, 1H), 7.47 (d, J = 8.79 Hz, 1H), 7.17 (d, J = 8.79 Hz, 1H), 4.06 (s, 3H), 2.57 (s, 3H), 2.19 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 16.3, 147.7, 140.3, 131.6, 120.2, 115.9, 105.8, 110.8, 37.2, 24.6, 9.9. ESI-MS m/z 204.06 $[\text{M}+\text{H}]^+$.

***N*-Isopropyl-1-methyl-1H-indazol-6-amine (24).** Prepared from compound **16** and acetone following the general procedure 3 to afford a reddish solid, yield 91.5%. mp 78-80 °C. IR (KBr, cm^{-1}): 3265 (NH amine); 3064 (CH aromatic); 1625 (C=N); 1573, 1436 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.74 (d, J = 0.72 Hz, 1H), 7.42 (d, J = 8.43 Hz, 1H), 6.45 (dd, J = 8.58, 1.83 Hz, 1H), 6.33 (s, 1H), 3.93 (s, 3H), 3.69 (hep, J = 6.24 Hz, 1H), 1.25 (d, J = 6.24 Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 146.2, 141.9, 132.7, 121.7, 117.1, 112.7, 88.6, 44.8, 35.2, 22.6. ESI-MS m/z 190.10 $[\text{M}+\text{H}]^+$.

***N*-Cyclopentyl-1-methyl-1H-indazol-6-amine (25).** Prepared from compound **16** and cyclopentanone following the general procedure 3 to afford a pink solid, yield 90.7%. mp 93-95 °C. IR (KBr, cm^{-1}): 3309 (NH amin); 3099 (CH aromatic); 1625 (C=N); 1573, 1435 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.69 (d, J = 0.75 Hz, 1H), 7.35 (d, J = 8.61 Hz, 1H), 6.39 (dd, J = 8.61, 2.01 Hz, 1H), 6.25 (s, 1H), 3.88 (s, 3H), 3.84-3.75 (m, 1H), 2.05-1.93 (m, 2H), 1.72-1.44 (m, 6H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 146.6, 141.8, 132.7, 121.6, 117.1, 112.7, 88.8, 55.3, 35.2, 33.3, 24.1. ESI-MS m/z 216.15 $[\text{M}+\text{H}]^+$.

***N*-Cyclohexyl-1-methyl-1H-indazol-6-amine (26).** Prepared from compound **16** and cyclohexanone following the general procedure 3 to afford a reddish solid, yield 90.3%. mp 101–103 °C. IR (KBr, cm^{-1}): 3331 (NH amin); 3099 (CH aromatic); 1625 (C=N); 1573, 1436 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.68 (s, 1H), 7.36 (d, J = 8.79 Hz, 1H), 6.39 (dd, J = 8.58, 1.65 Hz, 1H), 6.23 (s, 1H), 3.87 (s, 3H), 3.71 (br, 1H), 3.31-3.25 (m, 1H), 2.06-2.03 (m, 2H), 1.75-1.70 (m, 2H), 1.63-1.55 (m, 1H), 1.42-1.30 (m, 2H), 1.25-1.08 (m, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 145.6, 141.8, 132.7, 121.7, 117.4, 112.7, 89.3, 35.3, 32.9, 25.8 (2C), 24.9 (2C). ESI-MS m/z 230.16 $[\text{M}+\text{H}]^+$.

***N*-Benzyl-1-methyl-1H-indazol-6-amine (27).** Prepared from compound **16** and benzaldehyde following the general producer 3 to afford a reddish solid, yield 94.1%. mp 106-108 °C. IR (KBr, cm^{-1}): 3414 (NH amin); 3290 (CH aromatic); 1625 (C=N); 1571, 1436 (C=C aromatic). ^1H NMR (300 MHz,

CDCl₃, ppm): δ 7.70 (s, 1H), 7.39 (d, J = 8.79 Hz, 1H), 7.36-7.20 (m, 5H), 6.47 (dd, J = 8.58, 1.83 Hz, 1H), 6.30 (s, 1H), 4.33 (s, 2H), 4.21 (br, 1H), 3.84 (s, 3H). ¹³C NMR (125 MHz, *CDCl₃*, ppm): δ 147.3, 141.8, 138.7, 132.7, 128.8, 127.7, 127.5, 121.7, 117.3, 112.2, 88.1, 48.6, 35.2. ESI-MS m/z 238.17 [M+H]⁺.

1-Methyl-*N*-(pyridin-3-ylmethyl)-1*H*-indazol-6-amine (28). Prepared from compound **16** and 3-pyridinecarboxaldehyde following the general procedure 3 to afford a red solid, yield 94.3%. mp 117-119 °C. ¹H NMR (300 MHz, *CDCl₃*, ppm): δ 8.61 (s, 1H), 8.49 (d, J = 3.66 Hz, 1H), 7.71 (s, 1H), 7.67 (d, J = 7.89 Hz, 1H), 7.41 (d, J = 8.61 Hz, 1H), 7.22 (dd, J = 7.68, 4.77 Hz, 1H), 6.48 (dd, J = 8.61, 1.83 Hz, 1H), 6.25 (s, 1H), 4.37 (s, 2H), 4.26 (br, 1H), 3.83 (s, 3H). ¹³C NMR (125 MHz, *CDCl₃*, ppm): δ 149.0, 148.7, 146.9, 141.6, 135.3, 134.5, 132.7, 123.7, 121.8, 117.4, 112.0, 88.1, 45.9, 35.2. ESI-MS m/z 239.17 [M+H]⁺.

***N*-(4-Fluorobenzyl)-1-methyl-1*H*-indazol-6-amine (29).** Prepared from compound **16** and 4-fluorobenzaldehyde following the general procedure 3 to afford a red solid, yield 95.1%. mp 118-120 °C. IR (KBr, *cm⁻¹*): 3414 (NH amine); 3300 (CH aromatic); 1625 (C=N); 1571, 1436 (C-C aromatic); 1226 (C-F). ¹H NMR (300 MHz, *CDCl₃*, ppm): δ 7.71 (s, 1H), 7.39 (d, J = 8.61 Hz, 1H), 7.30 (dd, J = 8.43, 5.49 Hz, 2H), 6.98 (t, J = 8.61 Hz, 2H), 6.46 (dd, J = 8.61, 1.86 Hz, 1H), 6.25 (s, 1H), 4.30 (s, 2H), 4.19 (br, 1H), 3.84 (s, 3H). ¹³C NMR (125 MHz, *CDCl₃*, ppm): δ 163.2-161.2 (d, ¹ J_{C-F} = 243.8 Hz), 146.8, 141.5, 133.8, 132.6, 129.4-129.4 (d, ³ J_{C-F} = 7.5 Hz), 121.8, 115.6-115.5 (d, ² J_{C-F} = 21.3 Hz), 112.4, 92.0, 48.4, 35.2. ESI-MS m/z 256.20 [M+H]⁺.

***N*-(3-Fluorobenzyl)-1-methyl-1*H*-indazol-6-amine (30).** Prepared from compound **16** and 3-fluorobenzaldehyde following the general procedure 3 to afford a pink solid, yield 95.4%. mp 115-118 °C. IR (KBr, *cm⁻¹*): 3414 (NH amine); 2985 (CH aromatic); 1627 (C=N); 1575, 1481 (C-C aromatic); 1226 (C-F). ¹H NMR (300 MHz, *CDCl₃*, ppm): δ 7.76 (d, J = 0.72 Hz, 1H), 7.44 (d, J = 8.61 Hz, 1H), 7.30 (dt, J = 5.85, 7.86 Hz, 1H), 7.17 (d, J = 7.50 Hz, 1H), 7.10 (d, J = 9.69 Hz, 1H), 6.96 (td, J = 8.61, 2.58 Hz, 1H), 6.52 (dd, J = 8.79, 2.04 Hz, 1H), 6.29 (s, 1H), 4.40 (s, 2H), 4.32 (br, 1H), 3.80 (s, 3H). ¹³C NMR (125 MHz, *CDCl₃*, ppm): δ 164.1-162.2 (d, ¹ J_{C-F} = 245 Hz), 146.8; 141.5-141.4 (d, ³ J_{C-F} = 7.5 Hz), 132.7, 130.2-130.2 (d, ³ J_{C-F} = 8.8 Hz), 122.9-122.9 (d, ⁴ J_{C-F} = 2.5 Hz), 121.8, 117.4, 114.4-114.2 (d, ² J_{C-F} = 22.5 Hz, 2C), 112.1, 48.1, 35.2. ESI-MS m/z 256.20 [M+H]⁺.

***N*-Isopropyl-1,3-dimethyl-2*H*-indazol-6-amine (31).** Prepared from compound **17** and acetone following the general procedure 3 to afford a reddish solid, yield 89.7%. mp 119-221°C. ¹H NMR (300 MHz, *CDCl₃*, ppm): δ 7.33 (d, J = 8.61 Hz, 1H), 6.39 (dd, J = 8.58, 1.83 Hz, 1H), 6.23 (d, J = 1.83 Hz, 1H), 3.85 (s, 3H), 3.69 (hep, J = 6.21 Hz, 1H), 3.67 (br, 1H), 2.44 (s, 3H), 1.24 (d, J = 6.21 Hz, 6H). ¹³C NMR (125 MHz, *CDCl₃*, ppm): δ 146.4, 142.8, 141.2, 121.0, 116.4, 111.5, 88.5, 44.7, 34.8, 22.7,

11.7. ESI-MS m/z 2204.10 $[M+H]^+$.

N-Cyclopentyl-1,3-dimethyl-1H-indazol-6-amine (32). Prepared from compound **17** and cyclopentanone following the general procedure 3 to afford a reddish solid, yield 94.3%. mp 125-127°C. 1H NMR (500 MHz, $CDCl_3$, ppm): δ 7.32 (d, J = 8.60 Hz, 1H), 6.40 (dd, J = 8.65, 1.75 Hz, 1H), 6.24 (d, J = 1.30 Hz, 1H), 3.85-3.81 (m, 5H), 2.44 (s, 3H), 2.06 (hex, J = 6.20 Hz, 2H), 1.77-1.70 (m, 2H), 1.68-1.62 (m, 2H), 1.54-1.48 (m, 2H). ^{13}C NMR (125 MHz, $CDCl_3$, ppm): δ 147.2, 142.8, 141.1, 120.9, 116.2, 111.5, 88.2, 54.9, 34.8, 33.4, 24.1, 11.7. ESI-MS m/z 256.20 $[M+H]^+$.

N-Cyclohexyl-1,3-dimethyl-1H-indazol-6-amine (33). Prepared from compound **17** and cyclohexanone following the general procedure 3 to afford a reddish solid, yield 87.3%. mp 120-122°C. 1H NMR (300 MHz, $CDCl_3$, ppm): δ 7.34 (d, J = 8.61 Hz, 1H), 6.47 (d-like, 1H), 6.35 (s, 1H), 3.85 (s, 3H), 3.35-3.25 (m, 1H), 2.44 (s, 3H), 2.15-2.05 (m, 2H), 1.76-1.60 (m, 3H), 1.40-1.24 (m, 5H). ^{13}C NMR (125 MHz, $CDCl_3$, ppm): δ 146.5, 142.8, 141.1, 121.0, 116.3, 111.4, 88.2, 70.3, 35.5, 33.2, 24.9, 24.1, 11.7. ESI-MS m/z 244.10 $[M+H]^+$.

N-Benzyl-1,3-dimethyl-1H-indazol-6-amine (34). Prepared from compound **17** and benzaldehyde following the general procedure 3 to afford a reddish solid, yield 92.1%. mp 127-129°C. 1H NMR (300 MHz, $CDCl_3$, ppm): δ 7.40-7.28 (m, 6H), 6.50 (dd, J = 8.61, 1.83 Hz, 1H), 6.27 (d, J = 1.83 Hz, 1H), 4.38 (s, 2H), 3.83 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, $CDCl_3$, ppm): δ 147.6, 142.7, 141.2, 138.9, 128.7, 127.6, 127.4, 121.0, 116.5, 111.0, 87.9, 48.5, 34.8, 11.7. ESI-MS m/z 252.10 $[M+H]^+$.

1,3-Dimethyl-N-(pyridin-3-ylmethyl)-1H-indazol-6-amine (35). Prepared from compound **17** and 3-pyridinecarboxaldehyde following the general procedure 3 to afford a reddish solid, yield 81.5%. mp 107-109°C. 1H NMR (300 MHz, $CDCl_3$, ppm): δ 8.60 (d, J = 2.01 Hz, 1H), 8.48 (d, J = 3.30 Hz, 1H), 7.66 (d, J = 7.86 Hz, 1H), 7.33 (d, J = 8.67 Hz, 1H), 7.22 (dd, J = 7.89, 4.77 Hz, 1H), 6.44 (dd, J = 8.43 Hz, 1.86 Hz, 1H), 6.20 (d, J = 1.83 Hz, 1H), 4.37 (s, 2H), 4.22 (br, 1H), 3.77 (s, 3H), 2.40 (s, 3H). ^{13}C NMR (125 MHz, $CDCl_3$, ppm): δ 148.9, 148.6, 146.9, 142.5, 141.2, 135.3, 134.6, 123.7, 121.2, 116.8, 110.9, 88.2, 45.9, 34.8, 11.7. ESI-MS m/z 256.20 $[M+H]^+$.

N-(4-Fluorobenzyl)-1,3-dimethyl-1H-indazol-6-amine (36). Prepared from compound **17** and 4-fluorobenzaldehyde following the general procedure 3 to afford a reddish solid, yield 90.7%. mp 123-125°C. 1H NMR (500 MHz, $CDCl_3$, ppm): δ 7.38-7.33 (m, 3H), 7.03 (t, J = 8.60 Hz, 2H), 6.48 (dd, J = 8.60, 1.75 Hz, 1H), 6.25 (d, J = 1.35 Hz, 1H), 4.35 (s, 2H), 4.23 (bs, 1H), 3.82 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, $CDCl_3$, ppm): δ 163.1-161.1 (d, $^1J_{C-F}$ = 243.9 Hz), 147.3, 142.6, 141.2, 134.6-134.5 (d, $^4J_{C-F}$ = 3.3 Hz), 129.1-129.1 (d, $^3J_{C-F}$ = 7.9 Hz), 121.1, 116.6, 115.6-115.5 (d, $^2J_{C-F}$ = 21.4 Hz), 110.9, 88.0, 47.8, 34.9, 11.8. ESI-MS m/z 270.20 $[M+H]^+$.

N-(3-Fluorobenzyl)-1,3-dimethyl-1H-indazol-6-amine (37). Prepared from compound **17** and 3-fluorobenzaldehyde following the general procedure 3 to afford a reddish solid, yield 87.9%. mp 122-124°C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.37 (d, J = 8.95 Hz, 1H), 7.30 (td, J = 7.85, 6.20 Hz, 1H), 7.16 (d, J = 7.60 Hz, 1H), 7.09 (d, J = 9.65 Hz, 1H), 6.96 (td, J = 8.40, 2.50 Hz, 1H), 6.50 (dd, J = 8.60, 1.75 Hz, 1H), 6.23 (d, J = 1.25 Hz, 1H), 4.30 (s, 2H), 3.82 (s, 3H), 2.46 (s, 3H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 163.7–161.8 (d, $^1J_{\text{C-F}}$ = 241.8 Hz), 148.2, 143.8–143.8 (d, $^3J_{\text{C-F}}$ = 6.8 Hz), 143.0, 140.1, 130.7–130.6 (d, $^3J_{\text{C-F}}$ = 8.3 Hz), 123.8–123.8 (d, $^4J_{\text{C-F}}$ = 2.7 Hz), 120.8, 115.7, 114.4–114.3 (d, $^2J_{\text{C-F}}$ = 21.3 Hz), 113.9–113.8 (d, $^2J_{\text{C-F}}$ = 20.9 Hz), 111.5, 87.6, 46.5, 34.9, 11.9. ESI-MS m/z 270.20 $[\text{M}+\text{H}]^+$.

N-Isopropyl-2-methyl-2H-indazol-6-amine (38). Prepared from compound **18** and acetone following the general procedure 3 to afford a red solid, yield 96.1%. mp 114-116°C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.66 (s, 1H), 7.36 (d, J = 8.85 Hz, 1H), 6.62 (s, 1H), 6.46 (dd, J = 8.90, 1.55 Hz, 1H), 4.08 (s, 3H), 3.65 (hep, J = 6.25 Hz, 1H), 1.23 (d, J = 6.20 Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 151.0, 145.6, 123.5, 120.4, 116.6, 116.2, 92.9, 44.3, 39.7, 22.7. ESI-MS m/z 190.10 $[\text{M}+\text{H}]^+$.

N-Cyclopentyl-2-methyl-2H-indazol-6-amine (39). Prepared from compound **18** and cyclopentanone following the general procedure 3 to afford a reddish solid, yield 88.9%. mp 116-118°C. IR (KBr, cm^{-1}): 3286 (NH amin); 3080 (CH aromatic); 1631 (C=N); 1564, 1496 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.60 (s, 1H), 7.31 (d, J = 8.79 Hz, 1H), 6.54 (s, 1H), 6.40 (dd, J = 8.79, 2.01 Hz, 1H), 4.03 (s, 3H), 3.81–3.71 (m, 1H), 2.03–1.96 (m, 2H), 1.69–1.43 (m, 6H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 150.7, 146.7, 124.1, 120.4, 116.5, 115.6, 91.2, 54.1, 39.5, 32.8, 24.3. ESI-MS m/z 216.10 $[\text{M}+\text{H}]^+$.

N-Cyclohexyl-2-methyl-2H-indazol-6-amine (40). Prepared from compound **18** and cyclohexanone following the general procedure 3 to afford a reddish solid, yield 87.0%. mp 120-122°C. IR (KBr, cm^{-1}): 3271 (NH amin); 3115 (CH aromatic); 1635 (C=N); 1562, 1494 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.67 (s, 1H), 7.38 (d, J = 8.97 Hz, 1H), 6.71 (s, 1H), 6.53 (d, J = 9.15 Hz, 1H), 4.09 (s, 3H), 3.38–3.28 (m, 1H), 2.13–2.09 (m, 2H), 1.72–1.61 (m, 3H), 1.37–1.18 (m, 5H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 150.8, 146.0, 124.1, 120.6, 116.5, 115.6, 90.9, 51.1, 39.5, 32.8, 26.2, 25.0. ESI-MS m/z 230.10 $[\text{M}+\text{H}]^+$.

N-Benzyl-2-methyl-2H-indazol-6-amine (41). Prepared from compound **18** and benzaldehyde following the general procedure 3 to afford a reddish solid, yield 79.8%. mp 124-126°C. IR (KBr, cm^{-1}): 3309 (NH amin); 3118 (CH aromatic); 1635 (C=N); 1562, 1494 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.61 (s, 1H), 7.35–7.19 (m, 6H), 6.56 (s, 1H), 6.48 (dd, J = 8.79, 2.01 Hz, 1H), 4.29 (s, 2H), 4.02 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 150.7, 146.4, 139.1, 128.6, 127.7, 127.2, 123.5, 120.4, 116.4, 116.1, 92.9, 48.5, 39.7. ESI-MS m/z 238.17 $[\text{M}+\text{H}]^+$.

2-Methyl-N-(pyridin-3-ylmethyl)-2H-indazol-6-amine (42). Prepared from compound **18** and 3-pyridinecarboxaldehyde following the general procedure 3 to afford a reddish solid, yield 76.9%. mp 109-111°C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 8.65 (s, 1H), 8.51 (d, J = 3.00 Hz, 1H), 7.73 (d, J = 7.50 Hz, 1H), 7.69 (s, 1H), 7.43 (d, J = 9.00 Hz, 1H), 7.25 (dd, J = 5.50, 2.50 Hz, 1H), 6.59 (s, 1H), 6.57 (dd, J = 9.00, 2.00 Hz, 1H), 4.40 (s, 2H), 4.08 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 150.6, 149.2, 148.6, 145.9, 135.2, 134.6, 123.6, 123.5, 120.7, 116.6, 115.9, 93.3, 46.0, 39.8. ESI-MS m/z 238.17 $[\text{M}+\text{H}]^+$.

N-(4-Fluorobenzyl)-2-methyl-2H-indazol-6-amine (43). Prepared from compound **18** and 4-fluorobenzaldehyde following the general procedure 3 to afford a reddish solid, yield 78.9%. mp 114-116°C. IR (KBr, cm^{-1}): 3261 (NH amine); 3120 (CH aromatic); 1633 (C=N); 1562, 1502 (C=C aromatic); 1222 (C-F aromatic). ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.66 (s, 1H), 7.39 (d, J = 8.85 Hz, 1H), 7.34 (dd, J = 8.30, 5.60 Hz, 2H), 6.99 (t, J = 8.65 Hz, 2H), 6.57 (s, 1H), 6.53 (dd, J = 8.95, 1.90 Hz, 1H), 4.31 (s, 2H), 4.01 (s, 3H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 162.5-160.6 (d, $^1J_{\text{C-F}}$ = 240 Hz), 150.5, 146.6, 136.7-136.6 (d, $^4J_{\text{C-F}}$ = 2.9 Hz), 129.6-129.5 (d, $^3J_{\text{C-F}}$ = 8.0 Hz), 124.3, 120.7, 116.2, 115.9, 115.5-115.3 (d, $^2J_{\text{C-F}}$ = 21.0 Hz), 91.6, 46.4. ESI-MS m/z 256.19 $[\text{M}+\text{H}]^+$.

N-(3-Fluorobenzyl)-2-methyl-2H-indazol-6-amine (44). Prepared from compound **18** and 3-fluorobenzaldehyde following the general procedure 3 to afford a reddish solid, yield 75.7%. mp 123-125°C. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.61 (s, 1H), 7.25 (d, J = 9.33 Hz, 1H), 7.20 (dt, J = 5.85, 7.86 Hz, 1H), 7.09 (d, J = 7.68 Hz, 1H), 7.03 (d, J = 9.54 Hz, 1H), 6.86 (td, J = 8.25, 2.19 Hz, 1H), 6.51-6.47 (m, 2H), 4.30 (s, 2H), 4.14 (br, 1H), 4.00 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 164.1-162.1 (d, $^1J_{\text{C-F}}$ = 245.0 Hz), 150.6, 146.2, 142.0-142.0 (d, $^3J_{\text{C-F}}$ = 6.8 Hz), 130.1-130.1 (d, $^3J_{\text{C-F}}$ = 8.1 Hz), 123.7, 122.9-122.7 (d, $^4J_{\text{C-F}}$ = 2.9 Hz), 120.6, 116.5, 116.1, 114.3-14.2 (d, $^2J_{\text{C-F}}$ = 21.6 Hz), 114.1-114.0 (d, $^2J_{\text{C-F}}$ = 21.1 Hz), 93.1, 47.9 (d, $^4J_{\text{C-F}}$ = 1.6 Hz), 39.8. ESI-MS m/z 256.19 $[\text{M}+\text{H}]^+$.

N-Isopropyl-2,3-dimethyl-2H-indazol-6-amine (45). Prepared from compound **19** and acetone following the general procedure 3 to afford a pink solid, yield 95.6%. mp 116-118°C. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.27 (d, J = 8.79 Hz, 1H), 6.51 (d, J = 1.47 Hz, 1H), 6.39 (dd, J = 8.79, 1.83 Hz, 1H), 3.95 (s, 3H), 3.65 (hep, J = 6.24 Hz, 1H), 3.49 (br, 1H), 2.50 (s, 3H), 1.22 (d, J = 6.24 Hz, 6H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 149.4, 145.8, 131.4, 120.1, 115.4, 115.3, 92.7, 44.3, 36.6, 22.7, 9.8. ESI-MS m/z 204.10 $[\text{M}+\text{H}]^+$.

N-Cyclopentyl-2,3-dimethyl-2H-indazol-6-amine (46). Prepared from compound **19** and cyclopentanone following the general procedure 3 to afford a reddish solid, yield 83.8%. mp 117-119°C. IR (KBr, cm^{-1}): 3263 (NH amin); 3084 (CH aromatic); 1631 (C=N); 1562, 1450 (C=C aromatic). ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.25 (d, J = 8.95 Hz, 1H), 6.52 (d, J = 1.40 Hz, 1H), 6.40 (dd, J =

8.85, 1.80 Hz, 1H), 3.96 (s, 3H), 3.81 (quintet, $J = 5.45$ Hz, 1H), 3.68 (br, 1H), 2.5 (s, 3H), 2.04 (hex, $J = 6.45$ Hz, 2H), 1.73-1.67 (m, 2H), 1.64-1.60 (m, 2H), 1.53-1.49 (m, 2H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 149.3, 146.5, 131.4, 119.9, 115.4, 115.3, 92.7, 54.7, 36.6, 33.4, 24.2, 9.8. ESI-MS m/z 230.19 $[\text{M}+\text{H}]^+$.

N-Cyclohexyl-2,3-dimethyl-2H-indazol-6-amine (47). Prepared from compound **19** and cyclohexanone following the general procedure 3 to afford a reddish solid, yield 91.2%. mp 116-118°C. IR (KBr, cm^{-1}): 3290 (NH amin); 3018 (CH aromatic); 1633 (C=N); 1560, 1448 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.21 (d, $J = 8.97$ Hz, 1H), 6.47 (d, $J = 1.65$ Hz, 1H), 6.35 (dd, $J = 8.97, 2.01$ Hz, 1H), 3.90 (s, 3H), 3.27-3.20 (m, 1H), 2.43 (s, 3H), 2.09-2.05 (m, 2H), 1.71-1.59 (m, 3H), 1.38-1.26 (m, 2H), 1.21-1.13 (m, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 149.4, 145.7, 131.4, 120.1, 115.4, 115.3, 92.6, 51.9, 36.6, 33.1, 26.0, 25.0, 9.8. ESI-MS m/z 244.1 $[\text{M}+\text{H}]^+$.

N-Benzyl-2,3-dimethyl-2H-indazol-6-amine (48). Prepared from compound **19** and benzaldehyde following the general procedure 3 to afford a red solid, yield 87.5%. mp 123-125°C. IR (KBr, cm^{-1}): 3246 (NH amin); 3022 (CH aromatic); 1635 (C=N); 1562, 1448 (C=C aromatic). ^1H NMR (300 MHz, CDCl_3 , ppm): δ 7.35-7.19 (m, 6H), 6.49 (d, $J = 1.83$ Hz, 1H), 6.42 (dd, $J = 8.97, 2.01$ Hz, 1H), 4.29 (s, 2H), 4.00 (br, 1H), 3.90 (s, 3H), 2.43 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 149.2, 146.6, 139.2, 131.5, 128.6, 127.7, 127.2, 120.1, 115.6, 114.8, 92.6, 48.5, 36.7, 9.8. ESI-MS m/z 252.09 $[\text{M}+\text{H}]^+$.

2,3-Dimethyl-N-(pyridin-3-ylmethyl)-2H-indazol-6-amine (49). Prepared from compound **19** and 3-pyridinecarboxaldehyde following the general procedure 3 to afford a red solid, yield 73.6%. mp 112-114°C. ^1H NMR (300 MHz, CDCl_3 , ppm): δ 8.66 (s, 1H), 8.51 (d, $J = 4.77$ Hz, 1H), 7.73 (d, $J = 7.68$ Hz, 1H), 7.33 (d, $J = 8.61$ Hz, 1H), 7.26-7.23 (m, 1H), 6.53-6.50 (m, 2H), 4.40 (s, 2H), 4.12 (br, 1H), 3.97 (s, 3H), 2.51 (s, 3H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 149.4, 148.9, 148.3, 146.6, 135.9, 135.5, 131.3, 123.8, 120.5, 115.3, 114.9, 91.5, 44.8, 36.9, 9.7. ESI-MS m/z 253.19 $[\text{M}+\text{H}]^+$.

N-(4-Fluorobenzyl)-2,3-dimethyl-2H-indazol-6-amine (50). Prepared from compound **19** and 4-fluorobenzaldehyde following the general procedure 3 to afford a reddish solid, yield 88.9%. mp 116-118°C. IR (KBr, cm^{-1}): 3257 (NH amin); 3070 (CH aromatic); 1637 (C=N); 1562, 1450 (C=C aromatic); 1224 (C-F aromatic). ^1H NMR (500 MHz, DMSO, ppm): δ 7.42 (m, 2H), 7.31 (d, $J = 9.00$ Hz, 1H), 7.14 (t, $J = 9.00$ Hz, 2H), 6.55 (dd, $J = 9.00, 2.00$ Hz, 1H), 6.13 (s, 1H), 4.26 (d, $J = 6.00$ Hz, 2H), 3.85 (s, 3H), 2.51 (s, 3H). ^{13}C NMR (125 MHz, DMSO, ppm): δ 162.5-160.5 (d, $^1J_{\text{C-F}} = 253.8$ Hz), 149.0, 146.8, 136.7-136.7 (d, $^4J_{\text{C-F}} = 2.5$ Hz), 129.5-129.5 (d, $^3J_{\text{C-F}} = 7.5$ Hz), 120.4, 115.5-115.3 (d, $^1J_{\text{C-F}} = 21.5$ Hz), 115.3, 115.0, 91.4, 46.5, 36.9, 9.7. ESI-MS m/z 270.18 $[\text{M}+\text{H}]^+$.

N-(3-Fluorobenzyl)-2,3-dimethyl-2H-indazol-6-amine (51). Prepared from compound **19** and

3-fluorobenzaldehyde following the general procedure 3 to afford a pink solid, yield 79.7%. mp 127-129°C. ^1H NMR (500 MHz, CDCl_3 , ppm): δ 7.30 (d, J = 8.75 Hz, 1H), 7.26 (dt, J = 6.15, 7.85 Hz, 1H), 7.15 (d, J = 7.60 Hz, 1H), 7.08 (d, J = 9.75 Hz, 1H), 6.91 (td, J = 8.55, 2.25 Hz, 1H), 6.50-6.48 (m, 2H), 4.35 (s, 2H), 4.13 (br, 1H), 3.94 (s, 3H), 2.48 (s, 3H). ^{13}C NMR (125 MHz, CDCl_3 , ppm): δ 164.1-162.2 (d, $^1J_{\text{C-F}}$ = 245.0 Hz), 149.0, 146.3, 142.1-142.0 (d, $^3J_{\text{C-F}}$ = 6.9 Hz), 131.7, 130.1-130.0 (d, $^3J_{\text{C-F}}$ = 8.1 Hz), 123.0-122.9 (d, $^4J_{\text{C-F}}$ = 2.8 Hz), 120.3, 115.7, 114.8, 114.3-114.2 (d, $^2J_{\text{C-F}}$ = 21.1 Hz), 141.0-113.9 (d, $^2J_{\text{C-F}}$ = 21.0 Hz), 92.7, 47.9-47.9 (d, $^4J_{\text{C-F}}$ = 1.6 Hz), 36.7, 9.8. ESI-MS m/z 270.20 $[\text{M}+\text{H}]^+$.

Docking simulation analysis of IDO1 and its inhibitors




Fig S1. The crystal structure and a docking model of IDO1-5PK. 5PK in the complex structure and the docking model are shown with yellow green and cyan stick models, respectively. Hem ion is shown in grey stick. Oxygen atoms are colored in red.










Fig S2. Effect of compound **36** on IDO1 expression in HCT116 cells: HCT116 cells were treated with indicated concentration of compound **36**. IDO1 expression was determined using Western blotting.

Table S1. IC₅₀ of compounds **22**, **35-37** on MRC5 cells

Compounds	Structure	IC ₅₀ ^a (μM)
22		3.7±1.0
35		9.4±4.1
36		11.81±2.9
37		2.6±0.3

[a] IC₅₀: The concentration (μM) of compounds that produces a 50% reduction cell growth. All the data were calculated from the experiments conducted in triplicate and repeated for at least three times. Data represents mean ± SD.

2D Spectra of compounds 12 -15









Fig S3. NOESY spectra of **12-15**. (A) NOESY correlation between proton signal from N-CH₃ (4.12 ppm) and H-7 (8.31 ppm) of compound **12**; (B) NOESY correlation between proton signal from N-CH₃ (4.23 ppm) and H-3 (7.95 ppm) of compound **14**. (C) NOESY correlation between proton signal from N-CH₃ (4.16 ppm) and H-7 (8.58 ppm) of compound **13**; NOESY correlation between proton signal from N-CH₃ (4.18 ppm) and 3-CH₃ (2.64 ppm) of compound **15**.

ALL ^1H NMR, ^{13}C NMR & MS SPECTRA OF THE FINAL COMPOUNDS

^1H NMR of compound 20




^{13}C NMR of compound 20




MS of compound 20


Sample Name	II34	Position	P1-F4	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II34.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/15/2017 11:53:23 AM




¹H NMR of compound 21



¹³C NMR of compound 21




MS of compound 21




¹H NMR of compound 22

II14 (MeOD, 500MHz)




¹³C NMR of compound 22




MS of compound 22


Sample Name	II24	Position	P1-F3	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II24.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/15/2017 11:42:52 AM




¹H NMR of compound 23




¹³C NMR of compound 23




MS of compound 23




¹H NMR of compound 24




¹³C NMR of compound 24




MS of compound 24



¹H NMR of compound 25




¹³C NMR of compound 25




MS of compound 25


Sample Name	Position	Instrument Name	User Name
II35	P1-A9	Instrument 1	IRM Calibration Status
Inj Vol	0.01	Sample	Not Applicable
Data Filename	II35_2.d	Comment	Acquired Time
	DIP-pos(30vs70_0.01u)		11/14/2017 5:33:39 PM



¹H NMR of compound 26




¹³C NMR of compound 26




MS of compound 26


Sample Name	Position	Instrument Name	Instrument 1	User Name
II36	P1-A8		Sample	
Inj Vol	InjPosition	SampleType		IRM Calibration Status
0.01				Not Applicable
Data Filename	ACQ Method	Comment	Acquired Time	
II36.d	DIP-pos(30vs70_0.01u		11/14/2017 3:37:45 PM	



¹H NMR of compound 27




¹³C NMR of compound 27




MS of compound 27


Sample Name	II37	Position	P1-A3	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II37.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 2:34:27 PM



¹H NMR of compound 28




¹³C NMR of compound 28




MS of compound 28


Sample Name	II38	Position	P1-F9	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II38.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/15/2017 1:17:50 PM




¹H NMR of compound 29




¹³C NMR of compound 29




MS of compound 29



¹H NMR of compound 30




¹³C NMR of compound 30



MS of compound 30


Sample Name	II40	Position	P1-B5	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II40.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 5:12:31 PM




¹H NMR of compound 31



¹³C NMR of compound 31




MS of compound 31




¹H NMR of compound 32

II15 (CDCl₃, 500MHz)




¹³C NMR of compound 32




MS of compound 32


Sample Name	III15	Position	P1-A7	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	III15.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 3:27:13 PM



¹H NMR of compound 33




¹³C NMR of compound 33




MS of compound 33


User Spectra



¹H NMR of compound 34




¹³C NMR of compound 34




MS of compound 34


User Spectra




¹H NMR of compound 35



¹³C NMR of compound 35




MS of compound 35




¹H NMR of compound 36

II 19 (CDCl₃, 500MHz)




¹³C NMR of compound 36

II 19(CDCl₃, 500MHz)




MS of compound 36

Sample Name	II19	Position	P1-B3	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II19_2.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 6:15:53 PM




¹H NMR of compound 37

II20 (CDCl₃, 500MHz)




¹³C NMR of compound 37




MS of compound 37

Sample Name	II20	Position	P1-F5	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II20.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/15/2017 12:14:33 PM




¹H NMR of compound 38

II23 (CDCl₃, 500MHz)




¹³C NMR of compound 38




MS of compound 38


User Spectra



¹H NMR of compound 39




¹³C NMR of compound 39




MS of compound 39


Sample Name	II25	Position	P1-B2	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II25_2.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 5:54:43 PM



¹H NMR of compound 40



¹³C NMR of compound 40



MS of compound 40


User Spectra

Spectrum Source
Peak (1) in "+ TIC Scan - II26.d"


Fragmentor Voltage
135

Collision Energy
0


Ionization Mode
ESI



¹H NMR of compound 41




¹³C NMR of compound 41




MS of compound 41

Sample Name	Position	Instrument Name	Instrument 1	User Name
II27	P1-F6			
Inj Vol	InjPosition	SampleType		IRM Calibration Status
0.01		Sample		Not Applicable
Data Filename	ACQ Method	Comment	Acquired Time	
II27.d	DIP-pos(30vs70_0.01u		11/15/2017 12:25:03 PM	



¹H NMR of compound 42




Current Data Parameters
NAME Tham-II-28
EXPNO 82
PROCNO 1

F2 - Acquisition Parameters
Date_ 20200512
Time 8.19
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 16
DS 2
SWH 10000.000 Hz
FIDRES 0.152588 Hz
AQ 3.2767999 sec
RG 191.38
DW 50.000 usec
DE 6.50 usec
TE 299.5 K
D1 1.00000000 sec
TD0 1

----- CHANNEL f1 -----
SFO1 500.1330885 MHz
NUC1 1H
P1 9.80 usec
PLW1 24.00000000 W

F2 - Processing parameters
SI 65536
SF 500.1300109 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

¹³C NMR of compound 42



Current Data Parameters
NAME Tham-II-28
EXPNO 83
PROCNO 1

F2 - Acquisition Parameters
Date_ 20200512
Time 8.48
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 533
DS 4
SWH 31250.000 Hz
FIDRES 0.476837 Hz
AQ 1.0485760 sec
RG 191.38
DW 16.000 usec
DE 6.50 usec
TE 300.2 K
D1 2.00000000 sec
D11 0.03000000 sec
TD0 1


----- CHANNEL f1 -----
SFO1 125.7703637 MHz
NUC1 13C
P1 9.50 usec
PLW1 90.00000000 W

----- CHANNEL f2 -----
SFO2 500.1320005 MHz
NUC2 1H
CPDPRG2 waltz16
PCPD2 80.00 usec
PLW2 24.00000000 W
PLW12 0.36015001 W
PLW13 0.23050000 W

F2 - Processing parameters
SI 65536
SF 125.7577885 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40


MS of compound 42

User Spectra




¹H NMR of compound 43

II29 (?) (CDCl₃, 500MHz)




¹³C NMR of compound 43




MS of compound 43


Sample Name	Position	Instrument Name	User Name
II29	P1-F7	Instrument 1	
Inj Vol	InjPosition	SampleType	IRM Calibration Status
0.01		Sample	Not Applicable
Data Filename	ACQ Method	Comment	Acquired Time
II29.d	DIP-pos(30vs70_0.01u		11/15/2017 12:46:13 PM



¹H NMR of compound 44




¹³C NMR of compound 44



MS of compound 44


Sample Name	II30	Position	P1-B4	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II30.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 5:01:58 PM



¹H NMR of compound 45




¹³C NMR of compound 45




MS of compound 45

Sample Name	II3	Position	P1-A4	Instrument Name	Instrument 1	User Name
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status
Data Filename	II3.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Not Applicable
						Acquired Time




¹H NMR of compound 46

II 5 (CDCl₃, 500MHz)




¹³C NMR of compound 46




MS of compound 47


Sample Name	Position	Instrument Name	User Name
IIS	P1-A5	Instrument 1	
Inj Vol	InjPosition	SampleType	IRM Calibration Status
0.01		Sample	Not Applicable
Data Filename	ACQ Method	Comment	Acquired Time
IIS.d	DIP-pos(30vs70_0.01u		11/14/2017 2:55:31 PM



¹H NMR of compound 47




¹³C NMR of compound 47




MS of compound 47


Sample Name	II6	Position	P1-B1	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II-6_2.d	ACQ Method	DIP-pos..m	Comment		Acquired Time	1/22/2018 2:21:06 PM



¹H NMR of compound 48




¹³C NMR of compound 48




MS of compound 48


Sample Name	II7	Position	P1-B2	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II-7_2.d	ACQ Method	DIP-pos.m	Comment		Acquired Time	1/22/2018 2:42:09 PM




¹H NMR of compound 49




¹³C NMR of compound 49




MS of compound 49



¹H NMR of compound 50




¹³C NMR of compound 50




MS of compound 50

Sample Name	Unavailable	Position	Unavailable	Instrument Name	Unavailable	User Name	Unavailable
Inj Vol	Unavailable	InjPosition	Unavailable	SampleType	Unavailable	IRM Calibration Status	Not Applicable
Data Filename	II-9_2.d	ACQ Method		Comment	Sample information is unavailable	Acquired Time	Unavailable




¹H NMR of compound 51

II10 (CDCl₃, 500MHz)



¹³C NMR of compound 51



MS of compound 51

Sample Name	II10	Position	P1-A2	Instrument Name	Instrument 1	User Name	
Inj Vol	0.01	InjPosition		SampleType	Sample	IRM Calibration Status	Not Applicable
Data Filename	II10.d	ACQ Method	DIP-pos(30vs70_0.01u	Comment		Acquired Time	11/14/2017 2:23:55 PM

